Importance of screening severe COVID-19 patients for IFN-?1, IL-6 and anti-S1 IgG levels

Basit Öğe Kaydı
dc.authorscopusid58569822500
dc.authorscopusid57219922088
dc.authorscopusid23003351400
dc.authorscopusid56495590200
dc.authorscopusid57212213434
dc.authorscopusid8953204500
dc.authorscopusid26664308000
dc.contributor.authorKenanoğlu, O.B.
dc.contributor.authorGül, A.
dc.contributor.authorCan, H.
dc.contributor.authorKarakavuk, M.
dc.contributor.authorErkunt, Alak, S.
dc.contributor.authorKorukluoğlu, G.
dc.contributor.authorAltaş, A.B.
dc.date.accessioned2024-08-25T18:38:31Z
dc.date.available2024-08-25T18:38:31Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractCytokine storm is an important cause of death in COVID-19 patients. A recent clinical study showed that administration of recombinant interferon lambda 1 (IFN-?1 or IL-29) may prevent severe COVID-19. On the other hand, IL-6 has been associated as a prognostic marker of worsening for COVID-19 patients. The objective of this study is to screen IFN-?1, IL-6 and antibody levels in consecutive serum sample sets of COVID-19 patients. A total of 365 serum samples collected from 208 hospitalized COVID-19 patients were analyzed for IFN-?1 and IL-6 levels as well as SARS-CoV-2 neutralizing antibodies and anti-S1 IgG antibodies. Analyses of serum samples for cytokine levels showed that IFN-?1 (>8 pg/mL) and IL-6 (>2 pg/mL) were detected in approximately 64% and 21% patients, respectively. A decrement in IFN-?1 levels and IL-6 levels above 35 pg/mL can be sign of clinical severity and upcoming dead. An increment in IL-6 levels wasn't detected in every COVID-19 patient but a decrement in IL-6 levels was related to clinical improvement. Importantly, the detection of IFN-?1 level together with an increase in anti-S1 IgG antibody response were observed in clinically improved patients. Screening severe COVID-19 patients for IFN-?1, IL-6, and anti-S1 IgG antibody levels during their hospital stay especially in intensive care units may be beneficial to monitor the clinical status and management of treatment strategies. Importantly, detection of IFN-?1 together with protective IgG antibody response can be an indication of clinical improvement in severe COVID-19 patients and these patients may be discharged from the hospital soon. © 2023 Elsevier Ltden_US
dc.description.sponsorshipTürkiye Bilimsel ve Teknolojik Araştırma Kurumu, TÜBİTAK: 18AG020en_US
dc.description.sponsorshipThis study was partly supported by the grant from The Scientific and Technological Research Council of Türkiye (TÜBİTAK; https://www.tubitak.gov.tr/) (Grant No: 18AG020) to EK and ŞT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We sincerely appreciate the encouragement and support from Prof. Hasan Mandal.en_US
dc.identifier.doi10.1016/j.cyto.2023.156357
dc.identifier.issn1043-4666
dc.identifier.scopus2-s2.0-85170423988en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.cyto.2023.156357
dc.identifier.urihttps://hdl.handle.net/11454/101051
dc.identifier.volume171en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAcademic Pressen_US
dc.relation.ispartofCytokineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectAnti-S1 antibodyen_US
dc.subjectCOVID-19en_US
dc.subjectCytokineen_US
dc.subjectIL-29en_US
dc.subjectIL-6en_US
dc.titleImportance of screening severe COVID-19 patients for IFN-?1, IL-6 and anti-S1 IgG levelsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu